Related Experiment Video
Updated: Feb 8, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
PATIENT PRIORITIES FOR TREATMENT ATTRIBUTES IN ADJUNCTIVE DRUG THERAPY OF SEVERE HYPERCHOLESTEROLEMIA IN GERMANY: AN
Axel C Mühlbacher1, Anika Kaczynski2, Franz-Werner Dippel3
1Hochschule Neubrandenburg;Gesellschaft für empirische Beratung GmbH (GEB)muehlbacher@hs-nb.de.
Objectives:
Severe hypercholesterolemia is a major cause of death in coronary heart disease. New adjunctive drug therapies have passed authorization processes and been launched recently. So far it is not known which properties of the new treatment options generate the highest benefit for patients. The aim was to evaluate patient priorities in the field of adjunctive drug therapy with apheresis. Therapy characteristics were examined as to their relevance to hypercholesterolemia patients.
Methods:
To identify all potential patient-relevant treatment characteristics, a systematic literature review and ten interviews with patients were conducted. Seven key characteristics were identified from the patient perspective. Patients' priorities were elicited using an analytic hierarchy process (AHP).
Results:
In total, N = 61 patients diagnosed with severe hypercholesterolemia and undergoing apheresis participated in the study. The analysis showed predominance for the attribute "reduction of LDL-C level in blood" (Wglobal:0.362). The "risk of myopathy" (Wglobal:0.164), "risk of neurocognitive impairment" (Wglobal:0.161) and "frequency of apheresis" (Wglobal:0.119) were ranked second, third and fourth. Subgroup analyses revealed that "frequency of apheresis" is of greater importance to younger patients, men and/or patients who indicated a reduction in quality of life due to apheresis.
Conclusions:
The essential decision criteria for optimal therapy from the patients' perspective were obtained. "Reduction of lipoprotein in blood" was ranked highest compared with the "mode of administration" and "side effects" characteristics. The study offers a transparent approach for the identification of patient priorities for adjunctive PCSK9-inhibitor therapy in apheresis-treated hypercholesterolemia. The project can be used by healthcare decision makers to understand the importance of each patient-relevant endpoint.
Insights
Patients with severe hypercholesterolemia prioritize LDL-C reduction above other factors in adjunctive apheresis therapy. Side effects and frequency of treatment are also key considerations.
Area of Science:
- Cardiology
- Pharmacoeconomics
- Patient-centered care
Background:
- Severe hypercholesterolemia significantly contributes to coronary heart disease mortality.
- Recent advancements include new adjunctive drug therapies for hypercholesterolemia management.
- Patient preferences for these new therapies remain largely uncharacterized.
Purpose of the Study:
- To identify and evaluate patient priorities for adjunctive drug therapies in hypercholesterolemia, specifically in the context of apheresis.
- To determine the relative importance of various therapy characteristics from the patient's perspective.
Main Methods:
- A systematic literature review and ten patient interviews were conducted to identify relevant treatment characteristics.
- An analytic hierarchy process (AHP) was employed to elicit and quantify patient priorities among seven key characteristics.
- Sixty-one patients with severe hypercholesterolemia undergoing apheresis participated.
Main Results:
- The most significant patient-valued attribute was "reduction of LDL-C level in blood" (Wglobal:0.362).
- "Risk of myopathy" (Wglobal:0.164), "risk of neurocognitive impairment" (Wglobal:0.161), and "frequency of apheresis" (Wglobal:0.119) were the next highest-ranked characteristics.
- Younger patients, men, and those reporting reduced quality of life due to apheresis placed greater importance on the "frequency of apheresis".
Conclusions:
- Patient priorities for adjunctive hypercholesterolemia therapy center on lipoprotein reduction, administration mode, and side effect profiles.
- This study provides a transparent methodology for understanding patient-centered endpoints in adjunctive PCSK9-inhibitor therapy for apheresis-treated hypercholesterolemia.
- Findings can guide healthcare decision-makers in optimizing treatment strategies based on patient values.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Attribution Theory
Drug Therapy
Antianxiety Medications
Fundamental Attribution Error
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Attribution

